RAD51功能检测作为卵巢癌同源重组缺陷候选检测
研究前瞻性收集CHIVA随机试验的155份卵巢癌肿瘤样本,用免疫荧光检测RAD51、GMN和gH2AX,以≤10%的GMN阳性肿瘤细胞具有≥5个RAD51焦点定义为RAD51-low。RAD51检测对92%样本有贡献,54%样本为RAD51-low(HRD),其对新辅助铂类总缓解率更高(P=0.04)且无进展生存期更长(P=0.02)。
要点
- RAD51功能检测在92%卵巢癌样本中可评估,54%为RAD51-low。
- RAD51-low肿瘤对新辅助铂类总缓解率更高(P=0.04)且无进展生存期更长(P=0.02)。
- 67%的BRCA突变肿瘤为RAD51-low,RAD51-high的BRCA突变肿瘤化疗缓解似乎更差(P=0.02)。
核心结论
- 卵巢癌存在高水平DNA损伤,但54%未能形成RAD51焦点,这些RAD51-low肿瘤倾向于对新辅助铂类更敏感。
- RAD51检测还识别出一部分RAD51-high的BRCA突变肿瘤,其对铂类反应意外地差。
研究设计与样本
- 前瞻性收集CHIVA随机试验(新辅助铂类±尼达尼布)的肿瘤样本,共155份可用。
- 对FFPE组织块进行RAD51、GMN和gH2AX免疫荧光检测。
- 若≤10%的GMN阳性肿瘤细胞具有≥5个RAD51焦点,则肿瘤定义为RAD51-low。
- BRCA突变通过NGS识别。
主要发现
- RAD51检测对92%的样本有贡献,NGS对77%的样本可用。
- gH2AX焦点证实存在显著的基线DNA损伤。
- 54%的样本经RAD51判定为HRD,其对新辅助铂类的总缓解率更高(P=0.04)且无进展生存期更长(P=0.02)。
- 67%的BRCA突变肿瘤经RAD51判定为HRD。
- 在BRCA突变肿瘤中,RAD51-high肿瘤对化疗的缓解似乎更差(P=0.02)。
关键数值与推荐
- RAD51-low定义:≤10%的GMN阳性肿瘤细胞具有≥5个RAD51焦点。
- RAD51检测对92%的样本有贡献,NGS对77%的样本可用。
- 54%的样本经RAD51判定为HRD,其对新辅助铂类总缓解率更高(P=0.04)且无进展生存期更长(P=0.02)。
- 67%的BRCA突变肿瘤经RAD51判定为HRD;BRCA突变中RAD51-high肿瘤对化疗缓解似乎更差(P=0.02)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: Homologous recombination deficiency (HRD), defined as BRCA1/2 mutation (BRCAmut) or high genomic instability, is used to identify ovarian cancer (OC) patients most likely to benefit from PARP inhibitors. While these tests are useful, they are imperfect. Another approach is to measure the capacity of tumor cells to form RAD51 foci in the presence of DNA damage using an immunofluorescence assay (IF). We aimed to describe for the first time this assay in OC and correlate it to platinum response and BRCAmut. METHODS: Tumor samples were prospectively collected from the randomized CHIVA trial of neoadjuvant platinum +/- nintedanib. IF for RAD51, GMN and gH2AX was performed on FFPE blocks. Tumors were considered RAD51-low if ≤10% of GMN-positive tumor cells had ≥5 RAD51 foci. BRCAmut were identified by NGS. RESULTS: 155 samples were available. RAD51 assay was contributive for 92% of samples and NGS available for 77%. gH2AX foci confirmed the presence of significant basal DNA damage. 54% of samples were considered HRD by RAD51 and presented higher overall response rates to neoadjuvant platinum (P = 0.04) and longer progression-free survival (P = 0.02). In addition, 67% of BRCAmut were HRD by RAD51. Among BRCAmut, RAD51-high tumors seem to harbor poorer response to chemotherapy (P = 0.02). CONCLUSIONS: We evaluated a functional assay of HR competency. OC demonstrate high levels of DNA damage, yet 54% fail to form RAD51 foci. These RAD51-low OC tend to be more sensitive to neoadjuvant platinum. The RAD51 assay also identified a subset of RAD51-high BRCAmut tumors with unexpected poor platinum response.
引用
- Blanc-Durand F, Yaniz-Galende E, Llop-Guevara A, et al. A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer. Gynecol Oncol. 2023. PMID: 36868112. doi:10.1016/j.ygyno.2023.01.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。